Cipla Limited (NSE:CIPLA)
India · Delayed Price · Currency is INR 1,541.20
-12.20 (-0.79%)
Sep 8, 2025, 3:30 PM IST
Cipla Revenue
Cipla had revenue of 68.37B INR in the quarter ending June 30, 2025, with 3.20% growth. This brings the company's revenue in the last twelve months to 274.80B, up 6.13% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
274.80B
Revenue Growth
+6.13%
P/S Ratio
4.53
Revenue / Employee
9.07M
Employees
30,313
Market Cap
1,244.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Apollo Hospitals Enterprise | 225.51B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 236.08B |
| Fortis Healthcare | 80.94B |
| Alkem Laboratories | 133.04B |
| Aurobindo Pharma | 320.25B |
Cipla News
- 2 days ago - Nifty top losers this week (ending September 5): HCL Technologies, Wipro, Cipla, Infosys, HDFC Life and more - Business Upturn
- 3 days ago - Nifty 50 top losers today, September 5: ITC, Cipla, HCL Technologies, TCS, Tech Mahindra and more - Business Upturn
- 18 days ago - Nifty 50 top gainers and losers today, August 21: Cipla, Dr. Reddy’s Laboratories, Bajaj Finserv among top performers - Business Upturn
- 4 weeks ago - Cipla receives VAI classification from USFDA for Bengaluru facility - Business Upturn
- 5 weeks ago - Nifty 50 top losers today, August 1: Sun Pharma, Dr. Reddy’s Laboratories, Adani Enterprises, Cipla and more - Business Upturn
- 5 weeks ago - Nifty top losers today, July 30: Tata Motors, Hero MotoCorp, Power Grid, Cipla, Bajaj Auto and more - Business Upturn
- 6 weeks ago - Nifty top gainers today, July 28: Shriram Finance, Cipla, Hero MotoCorp, Asian Paints, Hindustan Unilever and more - Business Upturn
- 6 weeks ago - Top stocks to buy this week: What's the outlook for Nifty? Check stock recommendations - The Times of India